tirzepatide pulled from market FDA says shortage is over after taking a second look FDA's tirzepatide decision creates uncertainty

Description

Vomiting[1]is a common side effect

Any visible particles, cloudiness, color changes, or other abnormalities indicate potential contamination or degradation, and the vial should not be used

These parts help control how much you want to eat and how well your body uses insulin

Twelve or more weeks of dose escalation, managing side effects, adapting to reduced appetite

RD, 0.08% [95% CI, 0.02 to 0.15]) Proportion of individuals with newly diagnosed AF who were initiated on oral anticoagulants was not different in the screening (n=194, 73.5%) and control (n=172, 70.8%) arms (RD, 2.7% [95% CI, 5.5 to 10.4] 78.9 to 81.8% of participants treated with tirzepatide reported at least one adverse event that emerged during the treatment period as compared with 72.0% of participants in the placebo group Most frequently reported adverse events were gastrointestinal (nausea, diarrhea, and constipation) Serious adverse events were reported by 160 participants (6.3%) overall Approximately 21% of serious adverse events were considered to be related to coronavirus disease 2019 (Covid-19), which affected participants in all treatment groups Eleven deaths were reported: 4 (0.6%) in the 5-mg tirzepatide group, 2 (0.3%) in the 10-mg group, 1 (0.2%) in the 15-mg group, and 4 (0.6%) in the placebo group Four reported cases of adjudication-confirmed pancreatitis, evenly distributed across treatment groups, including the placebo group (none severe) No cases of medullary thyroid cancer were reported Reported incidence of cholelithiasis was similar among the tirzepatide and placebo groups Cholecystitis and acute cholecystitis were reported more frequently in the tirzepatide groups than in the placebo group Conclusions In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight